Clinical Trials Logo

Filter by:
NCT ID: NCT03006250 Recruiting - Clinical trials for Anesthesia; Adverse Effect

The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia

Start date: August 2016
Phase: Phase 4
Study type: Interventional

The effects of desflurane versus sevoflurane in adult patients undergoing LMA anesthesia on respiratory events during a less than 2-hour elective surgery.

NCT ID: NCT03003962 Active, not recruiting - Clinical trials for Non Small Cell Lung Carcinoma NSCLC

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Start date: January 2, 2017
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)

NCT ID: NCT03003533 Completed - Hemophilia A Clinical Trials

A Gene Transfer Study for Hemophilia A

Start date: January 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

NCT ID: NCT03001128 Completed - HIV-1 Infection Clinical Trials

Biomarkers to Predict Time to Plasma HIV RNA Rebound

Start date: February 23, 2017
Phase:
Study type: Observational

The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.

NCT ID: NCT02998645 Completed - Clinical trials for Severe Aplastic Anemia

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

SOAR
Start date: May 11, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of eltrombopag in combination with cyclosporine alone as first-line therapy on overall hematologic response

NCT ID: NCT02997579 Completed - Clinical trials for Vibroacoustic Signal

Comparison of Vibration Arthrometry Between Patella Resurfacing and Patella Non-resurfacing in Total Knee Replacement Patients

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

Patellar crepitus is a complication of total knee arthroplasty (TKA).The development of patellar crepitus after TKA are related to many factors such as femoral component design, surgical errors, and postoperative patellar baja. However, it is unclear whether patella resurfacing or patella non-resurfacing are associate with patellar crepitus. The primary objective of this study are to compare the prevalence of patellar crepitus and the mean value of vibroacoustic signal between patellar-resurfacing and patellar non-resurfacing in TKA. The secondary objective is to study the association between patellar crepitus and vibroacoustic signal.

NCT ID: NCT02995005 Completed - Hepatitis B Clinical Trials

Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus

Start date: May 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains the major mode of transmission in most high and intermediate HBV endemic areas, despite existing WHO immunoprophylaxis recommendations. This immunoprophylaxis regimen, if given optimally, can prevent 75-80% of HBV MTCT, but optimal implementation is difficult because it requires administering monovalent HBV vaccine and hepatitis B immunoglobulin (HBIg) within 24 hours of birth. Due to the barriers of giving HBIg, the World Health Organization (WHO) states, "…owing to concerns related to supply, safety and cost, the use of HBIg is not feasible in most settings." Clearly, global control of HBV transmission will require improved MTCT prevention. Therefore, the investigators hypothesize that treating HBV early in pregnancy will lead to undetectable HBV DNA levels at delivery and prevention of MTCT of HBV without HBIg; a concept that has already been proven with HIV. Tenofovir disoproxil fumarate (TDF), an approved anti-HBV drug, is promising to prevent MTCT of HBV due to its high potency against hepatitis B and its safety record in pregnant women. A randomized, controlled clinical trial (RCT) will be necessary to determine if TDF given to HBV-infected pregnant women early in pregnancy plus vaccine to the newborn can decrease MTCT of HBV without HBIg. However, before embarking on a RCT, several critical knowledge gaps need to be addressed including the ideal timing for TDF initiation. The purpose of this proposal is to address these knowledge gaps.

NCT ID: NCT02993393 Recruiting - Education Clinical Trials

A Comparative Study Between Simulation-based and Problem-based Learning in Difficult Airway Management Workshop

Start date: August 2015
Phase: N/A
Study type: Observational

Abstract Background and Goal of study Teaching and learning in airway management are essential in anesthetic field. Though simulation-based and problem-based learning are sophisticated learning tool, neither of them manifests the superior benefit. We would like to compare the teachers' and students' attitudes on these two learning methods. Material and Methods After IRB approval No. 369/2558(EC3). A prospective, questionnaires-based study was performed amongst volunteered, consent-signed, 10 anesthesiologists and 40 nurse anesthetist students. After stratified randomization, ten students simultaneously attended either SBL or PBL course one at a time. Six weeks later, a crossover technique was applied for both groups. At the end of project, teachers and students had to response to Likert's scale questionnaires. The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care. The students' questionnaire comprised 3 parts: learning content, process and evaluation. The validation of the questionnaire was determined by three board-certified anesthesiologists. The index of item objective congruence was 0.80 and 0.82 with Cronbach's Alpha of 0.97 and 0.92 respectively.

NCT ID: NCT02993224 Completed - Clinical trials for Transfusion-dependent Thalassemia

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

Jupiter
Start date: July 27, 2017
Phase: Phase 2
Study type: Interventional

Study to evaluate patient preference of deferasirox film-coated tablet (FCT) or deferasirox dispersible tablet (DT) in patient with transfusion - dependent thalassemia or non-transfusion -dependent thalassemia as measured by preference questionnaire at Week 48

NCT ID: NCT02992119 Completed - Malaria Vaccine Clinical Trials

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults

RTSS
Start date: June 4, 2017
Phase: Phase 2
Study type: Interventional

Targeted malaria elimination (TME), which comprises appropriate case management by village health workers, vector control and mass drug administration, is currently being implemented through pilot projects in selected villages in the Greater Mekong Subregion (GMS) and the scale-up of the intervention to the regional level are underway. Based on mathematical modelling, extending the post-TME parasitaemia-free period in the majority of villagers for as short as 200 days will substantially increase the chances of achieving the interruption of malaria transmission. Immunogenicity of RTS,S is greater in older children, and the short term malaria protective effect is stronger than the overall effect assessed over 1-2 years. Addition of mass RTS,S/AS01E vaccination to the TME arsenal could provide this much needed additional protection. Currently there are no safety and immunogenicity data for the use of RTS,S/AS01 in Asian populations. This trial will generate the required data for the use of this vaccine in Asian populations. For integration with the current TME activities, which provide mass drug administrations at months M0, M1, and M2, it would be most efficient and practical to provide the vaccine at the same intervals. To address a two round intervention (M0, M2) where a three round intervention is not feasible, one study arm will look at the immune response generated by only two doses of vaccine and antimalarial medications. Recent evidence suggests that a vaccination schedule which includes a fractional dose of RTS,S/AS01 (1/5th of the standard dose) could be similarly or more protective than a schedule with three standard full doses, while requiring less vaccine and resources. The trial therefore includes study arms which will assess the safety and immunogenicity of fractional dose schedules. Each participant will be randomized into one of the following study arms in a ratio of 20:20:30:30:30:30:30, as follows: - RTS,S/AS01B Fractional dose group (Group 1) - Double RTS,S /AS01E Fractional dose group (Group 2) - RTS,S/AS01E Standard dose group (Group 3) - RTS,S/AS01E + DHA-PIP+PQ Standard dose group (Group 4) - RTS,S/AS01E Fractional dose group (Group 5) - RTS,S/AS01E + DHA-PIP+PQ Fractional dose group (Group 6) - RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose group (Group 7)